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We have constructed chimeric papillomavirus-like particles (CVLPs) by replacing the 34-carboxy-terminal amino acids
of the HPV 16 L1 protein with various parts of the HPV 16 E7 protein. Chimeric proteins were expressed by recombinant
baculoviruses and analyzed by electron microscopy for their ability to assemble into virus capsids. We were able to
produce CVLPs in high efficiencies with inserts of up to 60 amino acids. CVLPs are able to induce a neutralizing
antibody response, assayed by inhibition of hemagglutination of mouse erythrocytes. CVLPs are interacting with the
putative receptor for papillomaviruses as they were shown to hemagglutinate mouse red blood cells and bind to and
penetrate cells in vitro. As CVLPs follow a similar intracellular pathway as observed earlier for BPV VLPs, we speculate
that CVLPs can be used to deliver peptides into mammalian cells in vitro and in vivo, possibly reaching the pathway
for MHC class I presentation. q 1997 Academic Press
INTRODUCTION epithelium (Crum et al., 1984). Today much is known
about the role of papillomavirus gene products in the
Cervical cancer is the leading cause of death from carcinogenesis of anogenital tumors (for review, see
a tumor in developing countries and every year 25,000 Gissmann, 1992; zur Hausen, 1989). Two early proteins
woman in the United States die of this type of cancer. of the high risk papillomaviruses, the E6 and E7 proteins
According to estimations by the World Health Organiza- are directly interfering with vital cell cycle control genes
tion, there are approximately half a million newly diag- (for review, see Sto¨ppler et al., 1994). Both proteins are
nosed cases of this disease worldwide annually (Pisani believed to be essential for the tumorigenic condition of
et al., 1993). Infection with certain human papillomavi- the cells. All HPV-positive cervical cancers analyzed
ruses (HPV), such as HPV type 16, was found to be critical were shown positive for E7 gene expression (Greenfield
for tumor development (for review, see Gissmann, 1992; et al., 1991, for review, see Wettstein, 1990). Even cell
zur Hausen, 1989). However, an antiviral vaccine might lines being cultured for decades but originally derived
eventually eliminate papillomavirus infection in man. This from HPV-induced tumors, like the HPV 18 containing
can be achieved by directing the immune system toward Hela cells, still express a functional E7 gene (Schwarz
either prevention of virus infection or elimination of virus- et al., 1985). In fact, E7-inactivation in cells in vitro leads
infected cells. to a growth arrest (von Knebel Doeberitz et al., 1988).
Different HPV types are inducing both benign and ma- Further, a significant portion of patients with invasive
lignant epithelial proliferations. Some types with a low cervical cancer exhibit E7-specific antibodies (Jochmus-
malignant potential, e.g., HPV type 11 are associated with Kudielka et al., 1989; Mu¨ller et al., 1992; Viscidi et al.,
benign mucosal tumors such as condylomata accumi- 1993; Jha et al., 1993).
nata (for review, see Ikenberg, 1991). However, even To generate infectious virus particles, papillomavi-
such infections are often accompanied by severe compli- ruses package their double-stranded circular genomes
cations, for instance in children suffering from HPV 11- into nonenveloped icosahedral virions with a T  7 sym-
induced laryngeal papillomas, making efforts in preven- metry and a diameter of 55 nm (Crawford and Crawford,
tion of so called ‘‘low risk’’ PV infections worthwhile. 1963; Galloway and McDougall, 1989; Baker et al., 1991).
Other HPV types, such as HPV 16, are involved in the Sixty hexavalent and 12 pentavalent pentameric-capso-
induction of malignant transformations of the anogenital meres, composed of the L1 major structural protein, are
forming the capsid into which the L2 minor structural
protein is incorporated (Favre et al., 1975). In recent years1 To whom correspondence and reprint requests should be ad-
it was shown that expression of the L1 protein in differentdressed. Fax: (708) 216 1196. E-mail: mmuelle@wpo.it.luc.edu.
eukaryotic systems leads to the formation of virus-like2 Present address: Lions Human Immunology Laboratories, Princess
Alexandra Hospital, Brisbane, Australia. particles (VLPs) (Sasagawa et al., 1995; Rose et al., 1993;
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Hagensee et al., 1993; Zhou et al., 1991b, 1993; Kirnbauer transport of these particles (Zhou et al., 1995). After this
‘‘pseudoinfection’’ we detected the capsid proteins de-et al., 1992; Heino et al., 1995; for review, see Schiller
and Roden, 1995). Coexpression of L1 and L2 seems to posited in the Golgi-apparatus, suggesting possible
channeling of the antigens into the MHC class I pathway.enhance particle formation and the L2 protein can be
detected in the capsids. VLPs have been used in different Indeed, there is evidence of the induction of cytotoxic T-
cells after the immunization of mice with VLPs (Schillerstudies to investigate virus–cell interaction. VLPs of dif-
ferent human papillomaviruses compete with infectious and Roden, 1995; W. M. Kast, personal communication).
Here we show that CVLPs (consisting of HPV 16 L1 andBPV virions for the same cellular receptor. Despite the
high tissue and host tropism of papillomaviruses, cells E7 fusion proteins) are structurally similar to VLPs, as
they are able to bind to the cellular receptor and thatof many different origins were shown to express the puta-
tive papillomavirus receptor in vitro (Roden et al., 1994a; they are inducing neutralizing antibodies. We expect that
CVLPs do have the potential to induce both a prophylac-Volpers et al., 1995; Mu¨ller et al., 1995).
After immunization with VLPs, neutralizing antibodies tic and a therapeutic immune response to papillomavirus
proteins.can be produced in different animal systems with high
efficiencies (Breitburd et al., 1995; Smith et al., 1995;
Roden et al., 1996a; Suzich et al., 1995). Despite the
MATERIAL AND METHODS
ability of PV-VLPs to bind to the same receptor molecule
and despite high sequence similarities of the major cap- Electron microscopy
sid proteins, neutralizing antibodies show only very little
cross-protection between different, even closely related Twenty-microliter samples of fractions from CsCl gra-
dients were dialyzed against 10 mM HEPES (pH 7.5) forPV types (Christensen et al., 1994; Roden et al., 1996b,
1994a; Volpers et al., 1995; Mu¨ller et al., 1995). Vaccina- 45 min on floating filter pads (0.02-mm pore size, Milli-
pore). Carbon-coated copper grids (200-mesh size; EMtion with VLPs leads to a long lasting protection against
virus challenge and it is believed that the major neutraliz- Sciences) were treated with 20 ml of Poly-L-Lysine (1 mg/
ml; Sigma) for 2 min. The sample was placed onto theing response is directed against the L1 protein, although
L2-specific neutralizing antibodies have been isolated grid for 2 min. Spotted grids were then stained with 30
ml of a 2% uranyl acetate solution for 2 min. Excess stainas well (Christensen et al., 1996b; Roden et al., 1994b;
Gaukroger et al., 1996). Theoretically devoid of any DNA was removed and grids were air dried. Specimens were
then examined with a Zeiss EM 900 electron microscopeand therefore considered noninfectious, a capsid-based
vaccine meets high safety standards. Taken together, at 80 kV. For immunogold staining, the dialyzed sample
was applied to the grid as described above. Grids werethese observations make VLPs prime candidates for the
development of a prophylactic vaccine based on the in- then blocked with 0.5% BSA in PBS for 30 min. Anti-HPV
16 E7 antibody (Triton, 1:20 in PBS/BSA) was added forduction of a protective antibody repertoire in humans
before they become exposed to papillomavirus infec- 1 hr at ambient temperature, followed by 1 hr incubation
with an immunogold-labeled (10-nm gold particle, Sigma)tions.
For patients already infected, virus-neutralizing anti- goat-anti mouse antibody. Grids were washed three
times with PBS, once with water, and then stained withbodies are of limited benefit. It is expected that eliciting
a virus-specific cytotoxic T-cell (CTL) response is re- uranyl-acetate as above.
quired to eliminate virus-infected cells (i.e., malignant or
premalignant cells). In a variety of different studies it was Construction of recombinant chimeric genes
convincingly shown that a competent cellular immune
response is able to control and eliminate PV infections The HPV 16 L1 open reading frame (ORF) was excised
from plasmid HPV16 – 114/k-L1/L2-pSynxtVI0 (Kirnbauer(for review, see Campo, 1994; Tindle and Frazer, 1994;
Altmann et al., 1994). Furthermore, it was demonstrated et al., 1994), using BglII and subcloned into pUC19 (New
England Biolabs) using the single BamHI site of thisthat regression of warts is systemic and can be induced
in animal systems by transfer of lymphocytes from ‘‘re- vector.
Generation of HPV 16 L1D310 constructs. Two primersgressor animals.’’ It was further observed that the preva-
lence of benign warts but also of premalignant lesions (CCCCGATATCGCCTTTAATGTATAAATCGTCTGG a n d
CCCCGATATCTCAAATTATTTTCCTACACCTAGTG) wereand cancer of the anogenital tract is increased in immu-
nosuppressed patients (for review, see Benton et al., designed to amplify the pUC19 vector and the complete
HPV 16 L1 ORF, except the nucleotides 6476– 6465. The1992). Rodents can be protected from tumor formation,
induced by HPV 16-transformed syngeneic cells, by vac- linear PCR product was cleaved with EcoRV and circular-
ized by ligation. DNA was transformed into Escherichiacination with E6- or E7-recombinant vaccinia virus or with
synthetic peptides (Feltkamp et al., 1993; Meneguzzi et coli and plasmids were screened for the presence of an
EcoRV restriction site. By this, a clone (HPV 16 L1 D310)al., 1991; Chen et al., 1991).
Recently, we have been able to show that exposure was generated harboring a 9-amino acid deletion (SGS-
TANLAS) at nt position 6476 in the L1 ORF. The cloneof cells to VLPs in vitro leads to binding, uptake, and
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was used to insert various DNA fragments of HPV 16, controlled using the NsiI restriction site in the E7 ORF.
All resulting constructs were excised with XbaI and SmaIsee below.
Generation of HPV 16 L1 DC and BPV 1 L1 DC con- and cloned into pVL1393 (Invitrogen) to generate recom-
binant baculoviruses.structs. Two primers (AAAGATATCTTGTAGTAAAAATTT-
GCGTCCTAAAGGAAAC and AAAGATATCTAATCTACC- Elimination of EcoRV sites. To generate clones HPV
16 L1DC* (Fig. 1C) two PCR reactions were performed toTCTACAACTGCTAAACGCAAAAAACG) complementary
to the HPV 16 L1 ORF were designed in a way that they amplify two overlapping fragments of clone pUC-HPV16
L1DC E7 1–50. The resulting DNA fragments overlappedwere facing each other backwards on the template (HPV
16 L1 in pUC19, see above). Both primers encoded 5* at the position of the L1/E7 boundary (‘Four primer PCR’
(Ho et al., 1989)). However, the primers did not containan EcoRV restriction site. In the downstream primer, the
EcoRV site was followed by a TAA translational stop the two EcoRV restriction sites. Fragment 1 was gener-
ated using primers P1: GTTATGACATACATACATTCT-codon to delete the last 34 amino acids of the HPV 16
L1 ORF. PCR was performed to amplify the complete L1 ATG (L1) and P2: CCATGCATTCCTGCTTGTAGTAAA-
AATTTGCGTCC (E7), fragment 2 using P3: CTACAAG-ORF plus the complete vector. The linear product was
cleaved with EcoRV, circularized with T4 DNA ligase, CAGGAATGCATGGAGATACACC (E7) and P4: CATCT-
GAAGCTTAGTAATGGGCTCTGTCCGGTTCTG (E7). One-and transformed into E. coli DH5 a cells. Clones were
analyzed for the presence of an EcoRV site, absent in tenth of the purified products was mixed and used as
template in a PCR reaction using primers P1 and P4 only.the vector or unmodified L1 ORF. The resulting construct
(pUCHPV16L1DC) was used to clone different fragments The resulting product was cleaved with EcoNI (L1) and
HindIII (downstream of the stop codon on primer P4) andof other HPV 16 ORFs (e.g., E7) into the newly generated
EcoRV site. used to replace an EcoNI/HindIII fragment of the cloned
HPV 16 L1 ORF. The resulting clone differs therefore fromAccordingly, we introduced an EcoRV site into the BPV
1 L1 ORF (subcloned into pUC19 at the BamHI restriction HPV16L1DC E7 1–50 by loss of the two internal EcoRV
restriction sites and the corresponding non-HPV aminosite) by PCR using the primers AAAGATATCTTGCTG-
TGCTAAAAATCTTCTTCCCAAGGG and AAAGATATC- acids Asp and Ile between the L1 ORF and E7 and down-
stream of E7. The first EcoRV site was replaced by theTGAGAAAACGAAGAATTAGCCAAAAAACTTCC. In BPV 1
L1DC the last 25 amino acids of BPV 1 L1 are deleted original L1 amino acids on this position (AlaGly), the
second was replaced by a translational stop signal. In(see Fig. 1).
Insertion of DNA fragments into clones HPV 16 L1 addition, this clone (HPV 16 L1DC* E7 1–52) contains
the first 52 amino acids of HPV 16 E7. Clone HPV 16D310, HPV16L1DC, and BPV 1 L1DC. Fragments of HPV
16 E7, encoding the amino acids 1–50, 1–60, 1– 98, 25 – L1DC* E7 1–52 was used to generate the resembling
clones HPV 16 L1DC* E7 1–55, 1–60, and 1–65 using75, 40–98, 50–98 were amplified using primers with a
5* EcoRV restriction site. We used the following primer primer P1 in combination with primer P5: CATCTGAAG-
CTTATCAATATTGTAATGGGCTCTGTCCG (E7 1–55); P6:pairs: E7 1–50: E7.1: AAAAGATATCATGCATGGAGATAC-
ACCTACATTGC and E7.2: TTTTGATATCGGCTCTGTC- CATCTGAAGCTTACTTGCAACAAAAGGTTACAATATT-
GTAATGGGCTCTGTCCG (E7 1–60); P7: CATCTGAAG-CGGTTCTGCTTGTCC; E7 1–60: E7.1 and E7.3: TTTTGA-
TATCCTTGCAACAAAAGGTTACAATATTGTAATGGGCC; CTTAAAGCGTAGAGTCACACTTGCAACAAAAGGTTA-
CAATATTGTAATGGGCTCTGTCCG (E7 1–65). HPV 16E7 1–98: E7.1 and E7.4: AAAAGATATCTGGTTTCTGAG-
AACAGATGGGGCAC; E7 25–75: E7.5: TTTTGATATCGA- L1DC* E7 1–70 was generated using clone HPV 16
L1DC* E7 1–65 and the primer P1 and P8: CATCTGAAG-TTATGAGCAATTAAATGACAGCTCAG and E7.6: TTT-
TGATATCGTCTACGTGTGTGCTTTGTACGCAC; E7 40 – CTTATTGTACGCACAACCGAAGCGTAGAGTCAC-
ACTTG. In all cases EcoNI and HindIII were used to98: E7.7: TTTATCGATATCGGTCCAGCTGGACAAGCA-
GAACCGGAC and E7.4; E7 50–98: E7.8: TTTTGATAT- replace the corresponding fragments. Clones were ana-
lyzed by DNA sequencing on an Applied BiosystemsCGATGCCCATTACAATATTGTAACCTTTTG and E7.4.
Part of the influenza matrix protein (nt 131–280; GenBank Prism 377 instrument using fluorescent chain terminating
dideoxynucleotides (Prober et al., 1987).No. X13413) was amplified with TTTTGATATCGATAT-
GGAATGGCTAAAGACAAGACCAATC and TTTTGATAT-
CGTTGTTTGGATCCCCATTCCCATTG. PCR products Generation of recombinant baculoviruses
were cleaved with EcoRV and inserted into the EcoRV
site of the modified L1 genes. To facilitate the identifica- Spodoptera frugiperda (Sf9) cells were grown in sus-
pension- or monolayer-cultures at 277 in TNMFH mediumtion of inserts in sense orientation, a ClaI restriction site
was included on the upstream primer for the generation (Sigma), supplemented with 10% fetal calf serum and 2
mM glutamine. For HPV 16 L1-based recombinant bacu-of clones E7 25–75, 50 –98, and the influenza matrix
protein. This site overlaps (GATATCGAT) with the EcoRV lovirus construction, 10 mg of transfer-plasmid were used
to transfect Sf9 cells together with 2 mg of linearizedrestriction site and encodes the amino acid aspartic acid.
For the three clones starting with amino acid 1 (methio- Baculo-Gold DNA (Pharmingen). Recombinant viruses
were purified by standard methods as suggested by thenine) of HPV16 E7, the orientation of the inserts was
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manufacturer. To test for expression of HPV 16 capsid CVLPs mixed 1:1 with complete (1st Immunization) or
incomplete Freund’s Adjuvants in a total volume of 100protein, 106 Sf9 cells were infected with baculovirus re-
combinants at a m.o.i. of 5 to 10. After incubation, medium ml. Six weeks after the third immunization mice were
sacrificed and blood was collected by cardiac puncture.was removed and cells were washed with PBS. The cells
were then lysed in SDS-sample buffer and analyzed by
Peptide ELISASDS-page and immune blotting assay.
Microtiter plates (Dynatech) were coated overnightPurification of virus-like particles
with 50 ml of peptide E701 ( (Mu¨ller et al., 1992), 10 mg/
Trichoplusia ni (TN) High Five cells were grown to a
ml PBS). After blocking for 2 hr at 377 with 100 ml of 5%
density of 1–2 1 106 cells per milliliter in Ex-Cell 405
BSA, 0.05% Tween 20 in PBS and three times washing
serum-free medium (JRH, Biosciences). Approximately 2
with PBS/0.05% Tween 20, 50 ml of sera was added at a1 108 cells were pelleted at 1000 g for 15 min, resus-
1:500 dilution in BSA/Tween 20/PBS for 1 hr. Plates were
pended in 20 ml of medium, and infected with recombi-
washed again and 50 ml of goat-anti-mouse peroxidase
nant baculoviruses at a m.o.i. of 2–5 for 1 hr at room
conjugate was added at a 1:5000 dilution. After 1 hr,
temperature. After addition of 200 ml of medium, cells
plates were washed and stained using ABTS substrate
were plated on round dishes and incubated for 3 – 4 days
(0.2 mg/ml 2,2*-Azino-bis(3-ethylbenzthiazoline-6-sul-
at 277. Cells were harvested, pelleted, and resuspended
fonic acid in 0.1 M Na-Acetate-Phoshate buffer (pH 4.2)
in 10 ml of extraction buffer. The following steps were
with 4 ml 30% H2O2 per 10 ml). Extinction was measuredperformed at 47. After sonication for 45 sec at 60 watts,
after 1 hr at 410 nm in a Dynatech automated plate
the extract was pelleted at 10,000 rpm in a Sorvall SS34
reader. As reference, we compared readings from wells
rotor. The pellet was resuspended in 6 ml of extraction
coated with peptide to wells coated with PBS only.
buffer, sonicated again for 30 sec at 60 watts, and centri-
fuged again. Combined supernatants were layered onto Antigen capture ELISA
a two-step gradient with 14 ml of 40% sucrose on top of
8 ml of CsCl solution (4.6 g CsCl per 8 ml extraction To allow relative quantification of virus-like particles in
fractions of CsCl gradients, we used an antigen capturebuffer) and centrifuged in a Sorvall AH629 swinging
bucket rotor for 2 hr at 27,000 rpm (107). The interphase ELISA. Microtiter plates were coated overnight with 50
ml/well of a 1:500 dilution (final concentration of 2 mgbetween CsCl and sucrose and the complete layer of
CsCl were collected and filled into 13.4 ml Quickseal per ml, in PBS) of protein A purified mouse monoclonal
antibody specific for HPV 16 L1 (antibodies 25/C, MM07,tubes. Extraction buffer was added to adjust the volume
to 13.4 ml. Samples were centrifuged overnight at 50,000 and Ritti1 were obtained from mice immunized with HPV
16 VLPs). Plates were blocked with 5% milk/PBS for 1 hrrpm at 207 in a Beckman 70 Ti rotor. Gradients were
fractionated (1 ml per fraction) by puncturing tubes on and 50 ml of fractions of CsCl gradients were added for
1 hr at 377, using a 1:300 dilution (in 5% milk/PBS). Aftertop and bottom with a 21-gauge needle. Then 2.5 ml of
each fraction were analyzed by a 10% SDS–polyacryl- three washings with PBS/0.05% Tween 20, 50 ml of a
polyclonal rabbit antiserum (1:3000 dilution in milk/PBS),amide gel and Western blotting.
For separation of VLPs and capsomeres we used sedi- raised against HPV 16 VLPs was added and plates were
incubated at 377 for 1 hr. Plates were then washed againmention of CVLPs on 10 –50% sucrose gradients. Peak
fractions of CsCl gradients were dialyzed for 2 hr against and further incubated with 50 ml/well of a goat-anti-rabbit
peroxidase conjugate (Sigma, 1:5000 in milk/PBS) for 15 mM HEPES (pH 7.5, 150 mM NaCl). Half of the material
was then used for disassembly overnight by adding hr. After final washing, plates were stained with ABTS
substrate for 30 min and extinction measured at 410 nmEDTA (final concentration 50 mM ), EGTA (50 mM), DTT
(30 mM), NaCl (100 mM), and Tris/HCl (pH 8.0, 10 mM). in a Dynatech automated plate reader (see above). As a
negative control, we used wells coated only with PBS.As control, we added to the other half NaCl and Tris/HCl
only. A 10–50% sucrose step gradient (containing 100 To test monoclonal antibodies for their capsomere-
respective capsid-specificity, we treated CVLPs andmM NaCl and 5 mM HEPES (pH 7.5)) was left overnight
at 47. For analysis of disassembled VLPs EDTA, EGTA, VLPs with EDTA/DTT to disassemble particles. Treated
particle preparations were then measured in the antigen-and DTT (each 5 mM final concentration) were added to
the sucrose cushions. Treated and untreated VLPs were capture ELISA and readings compared to untreated con-
trols. For disassembly, 40 ml of VLPs (CVLPs) was incu-layered on top of the gradient and centrifuged at 250,000
g for 2–4 hr at 47. Fractions were collected by puncturing bated overnight at 47 in 500 ml of disruption buffer (30
mM DTT, 50 mM EGTA, 50 mM EDTA, 100 mM NaCl,tubes from the bottom. A 1:10 dilution of each fraction
was then analyzed by antigen capture ELISA. 100 mM Tris/HCl (pH 8.0)). As control, we incubated the
same amount of VLPs (CVLPs) in 500 ml of dilution buffer
Production of antisera (100 mM NaCl, 100 mM Tris/HCl (pH 8.0)). Aliquots of
treated and untreated particles were then used in theBalb/c mice were immunized three times, every 4
weeks subcutaneously with approximately 50 mg of above capture ELISA in 1:20–1:40 dilutions. Readings
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from the treated fractions were compared to the controls involved in particle formation (Paintsil et al., 1996). We
found that the L1 protein is highly sensitive to the intro-(100% reactivity).
To compare the relative yields of VLPs measured by duction of mutations, since most of the clones failed to
assemble into virus-like particles (VLPs). However, a 25-ELISA, we analyzed twofold serial dilutions of extracts
of TN-High Five cells infected with L1 recombinant bacu- amino acid (aa) carboxy-terminal truncated L1 protein
was able to assemble into VLPs at even higher efficiencylovirus (expressing L1 or L1/E7 proteins) by Western blot.
Dilutions of different extracts that produced identical sig- than wild-type L1. In addition, 40-aa deletions at positions
311, 371, 391, and 411 did not completely abolish thenals in Western blot were then used to calculate relative
L1 content. ability of the L1 protein to oligomerize as judged by band-
ing in CsCl gradients, although electron microscopy re-
Immunofluorescence vealed that the formation of VLPs was impaired.
We used these observations to construct two modifiedCells were seeded into 8-well chamber slides (Nunc)
HPV 16 L1 ORFs (HPV 16 L1 D310 and HPV 16 L1 DC,and grown to 70% confluency. To study binding and up-
see Fig. 1). HPV 16 L1 D310 bears a 9-aa deletion at atake of virus-like particles, 10–50 ml of peak fractions
position corresponding to the BPV L1 mutant D311–351.from CsCl gradients were dialyzed against 10 mM
The 9-aa deletion was selected as it has only a lowHEPES, pH 7.5, for 1 hr and then added to 104 cells. The
amount of homology between PVs and it was believedchamber slides were incubated at 47 for 1 hr with gentle
to be less critical for capsid formation. In clone HPV 16shaking. Medium was replaced with fresh DMEM, 10%
L1DC the 34 carboxy-terminal amino acids were deleted,FCS, and cells were incubated at 377 for 2–4 hr or over-
corresponding to a 25-aa deletion in clone BPV 1 L1DCnight. For immunofluorescence, cells were washed twice
(see Fig. 1G). Both clones bear an EcoRV endo-restrictionwith PBS and fixed in ice-cold ethanol (100%) for 15 min.
site at the position of the deletions. We used this site toSlides were washed with PBS three times and then incu-
insert different parts of other ORFs to generate chimericbated at 377 with antibody (1:20 of Camvir1 or Triton anti-
papillomavirus particles (CVLPs; see Table 1). The EcoRVHPV 16 E7) diluted in milk (2% milk powder in PBS).
restriction site encodes the two additional, non-HPVCells were washed 5 times with PBS and incubated with
amino acids aspartic-acid and isoleucine. In clones hold-fluorescent labeled antibody (Sigma) as above. Finally,
ing the HPV 16 E7 inserts 25–75 and 50–98, and inthe slides were washed for 30 min in PBS, changing the
the clone with part of the influenza matrix protein, ansolution every 10 min. Coverslips were mounted with
additional aspartic acid is inserted after the isoleucine50% glycerol and slides were examined with a Nikon-
upstream of the insert.fluorescent microscope. As a negative control for immu-
nofluorescence using the anti-L1 antibody we used cells
Generation of chimeric papillomavirus particleswithout HPV16L1 DCL1 E7 CVLPs, for the anti-E7 anti-
body we examined cells incubated with HPV 16 L1 VLPs.
SF9 insect cells were infected with recombinant bacu-
loviruses expressing chimeric HPV 16 L1 proteins asHemagglutination assay
shown in Table 1. To test the different constructs for their
One hundred microliters of Heparin (1000 usp units/ ability to produce capsomeres or capsids, we subjected
ml) were added to 1 ml fresh mouse blood. Red blood extracts from infected cells to gradient centrifugation. We
cells were washed 3 times with PBS by centrifugation analyzed L1 protein-positive fractions (Western blotting)
and resuspension in a volume of 10 ml. Next, erythro- by electron microscopy. Table 1 shows the results for
cytes were resuspended in 0.5 ml of PBS and stored at CVLPs based on the three L1 proteins HPV 16 L1D310,
47 for up to 3 days. For hemagglutination, 70 ml of this BPV 1 L1DC, and HPV 16 L1DC, as described in Fig. 1.
suspension were used for a 96-well plate. All three modified L1 proteins, without inserts, were
VLP-positive aliquots from CsCl gradients were dia- able to produce VLPs. While the two carboxy-terminal
lyzed for 1 hr against 10 mM Hepes (pH 7.5) and 100 ml truncated proteins produced VLPs at comparable levels
of twofold serial dilutions in PBS were added to mouse as the wild-type L1 protein, the HPV 16 L1D310 construct
erythrocytes in round-bottom 96-well microtiter plates produced VLPs at relatively low levels, as we detected
which were then further incubated for 3–16 hr at 47. only elongated structures (as shown in Fig. 4C) or single
For hemagglutination inhibition, VLPs were preincubated particles by electron microscopy. We then used the three
with dilutions of antibodies in PBS for 60 min at room different L1 deletion mutants to insert DNA fragments of
temperature and then added to erythrocytes. different size and of different origin. We confirmed the
presence of the inserted (HPV 16 E7-derived) sequences
RESULTS in chimeric proteins by DNA-sequencing of the expres-
sion vectors and Western blot analysis of crude extractsDesign of chimeric L1 proteins
derived from baculovirus infected insect cells (see Fig.
2). Proof for presence of inserted sequences in virus-likeIn a recent study we investigated deletion mutants of
the BPV 1 L1 to identify regions of the capsid protein particles (construct HPV 16 L1DC* E7 1–55) was derived
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FIG. 1. Construction of chimeric virus-like particles. (A and B) construction of chimeras originating from HPV 16 L1 DC, in this example inserting
the HPV 16 E7 amino acids 1 – 50. (C) Clone HPV 16 L1 DC* E7 1–52 which was generated from HPV 16 L1DC E7 1–50 by replacing the two
EcoRV restriction sites by HPV-specific amino acids (Ala and Gly N-terminal, His and Tyr C-terminal of the E7-insert; (D and E) chimeras originating
from HPV 16 L1 D310, inserting HPV 16 E7 1–50. (F) BPV L1DC HPV 16 E7 1–50 was generated according to clone HPV 16 L1DC E7 1–50. (G)
Carboxy-terminal sequence of BPV 1 and HPV 16 L1. The arrows indicate where the EcoRV restriction sites and termination codons in clones HPV
16 L1DC and BPV 1 L1DC were introduced.
from Western blot analysis after sedimentation of CVLPs shown to assemble into VLPs with inserts ranging from
5 (RRGDL) to 50 amino acids of HPV 16 E7.on sucrose gradients (see Fig. 8). This was confirmed
by immunoflurorescence after ‘‘pseudoinfection’’ of mam- We observed efficient particle formation of HPV16
malian cells (see Fig. 6). L1DC-based constructs bearing N-terminal portions of
the HPV 16 E7 protein. Clone HPV16 L1DC E7 1–50As expected, the majority of the resulting chimeric L1
proteins showed a dramatically reduced ability to pro- produced high yields of particles with a structure indistin-
guishable from wild-type HPV 16 L1 (compare Fig. 3D toduce VLPs. We consistently failed to detect intact capsid
structures when we analyzed chimera based on the HPV 3F). Increasing the size of the insert by another 10 amino
acids (clone HPV16 L1DC E7 1–60) led to more hetero-16 L1D310 protein although some of them were still able
to assemble into capsomeres (see Table 1). Because of geneous appearance in size and form, indicating an im-
paired ability to assemble (see Fig. 3H). Increasing thethe deficiency of the HPV 16 L1D310 chimera to produce
VLPs, we did not further characterize this series of con- insert to full-size E7 (HPV16 L1DC E7 1–98) led to an
estimated 1000-fold reduced particle production as westructs.
observed, by electron microscopy, only occasionallyDifferent result were obtained analyzing recombinants
complete particles. However, in CsCl fractions slightlyof the two constructs HPV 16 L1DC and BPV 1 L1DC.
(0.04 g/ml) heavier than those in which we usually findWhile some inserts obviously completely abolished cap-
VLPs, we observed large arrays of capsomere-structuressid assembly, others were compatible with the formation
(see Figs. 4D and 4E). HPV16 L1DC-based clones withof VLPs. We observed that both the length of the insert
HPV 16 E7 inserts 25–75, 40–98, 50–98 also showedas well as the particular sequence have important influ-
highly reduced yields of VLPs. Taken together, these ob-ences on assembly efficiency. While some constructs
servations suggest that E7-specific sequences aroundtolerated inserts from HPV 16 E7 of up to 60 amino acids,
amino acids 55–70 are interfering with VLP assembly.a 10-aa-long insert, derived from the carboxy-terminus
of the SV 40 T-antigen, almost completely abrogated the Judging from the yield and morphology of the different
CVLP-constructs based on HPV 16 L1DC, we consideredassembly (see Table 1). The construct BPV 1 L1DC was
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TABLE 1
Chimeric Papillomaviruses and Their Characteristics
Insert
size Capsomere Capsid
No. L1 protein Inserta (aa)a CsCl yield yield Hemaggluttination HA-Inhibition
1 HPV 16 L1 None 0 / ///// ///// / /
2 BPV 1 L1 None 0 / ///// ///// / /
3 HPV 16 L1D 310 None 0 / /// // nt nt
4 HPV 16 L1DC None 0 / //// //// / /
5 HPV 11 L1DCb None 0 / //// //// nt nt
6 BPV1 DC None 0 / ///// ///// / /
7 BPV1 DC E7 25-75c 51 / // // nt 0
8 BPV1 DC 57 1-50 50 / / / nt nt
9 BPV1 DC E7 50-98c 49 / / / nt nt
10 BPV1 DC RRGDL 5 / //// //// nt nt
11 HPV 16 L1D 310 E7 1-98 98 //0 0 0 nt nt
12 HPV 16 L1D 310 E7 1-50 50 / // 0 nt nt
13 HPV 16 L1D 310 E7 25-75c 51 / 0 0 nt nt
14 HPV 16 L1D 310 E7 50-98c 49 / 0 0 nt nt
15 HPV 16 L1D 310 SV 40 tag 10 / / 0 nt nt
16 HPV 16 LIDC E7 1-98 98 / ///d / nt nt
17 HPV 16 L1DC E7 1-50 50 / //// ///// / /
18 HPV 16 L1DC E7 25-75c 51 / /// / nt nt
19 HPV 16 L1DC E7 50-98c 49 / / / nt nt
20 HPV 16 L1DC E7 1-60 60 / ///// ///// / /
21 HPV 16 L1DC E7 40-98 59 / //// 0 nt nt
22 HPV 16 L1DC SV 40 tag 10 / / 0 nt nt
23 HPV 16 L1DC Influenza 30 / /// / nt nt
24 HPV 16 L1DC* E7 1-52 52 / ///// ///// nt nt
25 HPV 16 L1DC* E7 1-55 55 / ///// ///// / nt
26 HPV 16 L1DC* E7 1-60 60 / /// //// nt nt
27 HPV 16 L1DC* E7 1-65 65 / // 0 nt nt
28 HPV 16 L1DC* E7 1-70 70 / // 0 nt nt
Note. Listed are the three different types of chimeric L1 proteins (HPV 16 L1D310, HPV 16 L1DC, and BPV 1 L1DC) and their inserts. A / under
CsCl means that L1 protein was detected in CsCl gradients at a density of 1.28 g/ml. The yield of capsomeres and capsids is given in five categories
as judged from independent purifications followed by electron microscopy, representing ///// similar to the amount of wt L1 and / in cases
where only occasionally single VLPs were found. Further, it is indicated whether CVLPs are hemaggluttination (HA)-positive and whether neutralizing
antibodies can be produced in mice using CVLPs as antigen.
a Recombinants 1– 4 and 6 bear a EcoRV restriction site and encode therefore the two non-L1 amino acids Asp and Ile, clones 7–23 bear two
EcoRV sites flanking the insert.
b Twenty carboxy-terminal aminoacids (aa) of HPV 11 were deleted in this clone.
c Due to the cloning strategy these CVLPs have an additional Asp inserted in front of the E7 insert.
d Arrays of capsomeres were observed in fractions with a density of 1.32 g/ml.
construct HPV 16 L1DC E7 1–50 to be the most efficient. struct HPV 16 L1DC* E7 1–60 the yield of particles was
reduced by about two orders of magnitude and no VLPsIn view of a possible use of CVLPs as a vaccine in hu-
mans, we decided to eliminate the non-HPV amino acids were found in case of constructs bearing E7 1–65 and
1–70. Again, this suggests that E7 amino acids beyondfrom the chimeric proteins that were encoded by the
EcoRV restrictions sites flanking the inserted gene. We amino acid position 55 are incompatible with correct cap-
sid assembly in these CVLP recombinants.designed a series of recombinants (HPV 16 L1DC*) in
which the 5* EcoRV site was replaced by the original When TN-High Five cells expressing different chimeric
L1 proteins were analyzed by immunofluorescence, weHPV 16 L1 amino acids (alanine and glycine) at this posi-
tion. The 3* EcoRV site was replaced by codons which found a predominant cytoplasmic localization of the chi-
meric L1 proteins (see Fig. 5). Even for the HPV 16 L1allowed the extension of the E7 insert. We designed a
series of CVLP constructs with increasing length of the DC E7 1–98 construct, which bears the complete nu-
clear HPV 16 E7 protein, the chimeric proteins showedE7 insert (HPV 16 L1DC* E7 1–52, 1–55, 1–60, 1 – 65,
and 1–70). Characteristics of these chimeric L1/E7 pro- a completely different cellular localization compared to
the wild-type HPV 16 L1 protein. We concluded that theteins are listed in Table 1. Constructs HPV 16 L1DC* E7
1–52 and HPV 16 L1DC* E7 1–55 produced high yields cytoplasmic localization of the truncated L1 protein is
caused by the loss of the carboxy-terminal nuclear local-of VLPs (see Figs. 3I, 4A, and 4B). However, for the con-
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lyzed three different anti-L1 monoclonal antibodies for
their specificity for capsomeres and/or capsids. CVLPs
or VLPs were treated with chelating and reducing agents
to allow disrupture of complete particles into capso-
meres. We found that two of the three antibodies (25/c
and Ritti1) were reacting with capsomeres as well as with
capsids since disruption of particles led to an increased
reactivity in ELISA. The third antibody (MM07) showed
a significantly decreased reactivity after disassembly of
VLPs and CVLPs, suggesting a specificity for intact VLPs/
CVLPs (see Fig. 7). Independently we tested whether this
decrease in reactivity with disassembled particles is due
to a sensitivity of this particular antibody toward EDTA
or DTT. However, preincubation of antibody MM07 with
even 10-fold higher concentrations of EDTA/DTT than
those used in the above experiment did not reduce the
reactivity in the ELISA. The observed antibody-specifici-
ties were confirmed by velocity centrifugation of intact
and disassembled CVLPs on sucrose gradients (see
Figs. 8A–8C). Antibodies 25/c and Ritti1 detected antigen
in gradient-fractions corresponding to intact VLPs as well
as capsomeres; antibody MM07 reacted with fractions
corresponding to VLPs only.
We then used the capsid-specific antibody to deter-
mine the particle yield of different CVLP-constructs. Ad-
justing the amount of L1 expression between the different
clones and scoring the yield of HPV 16 VLPs in this
experiment as 100%, we calculated 25–40% for HPV 16
L1DC E7 1–50, 20–30% for HPV 16 L1DC E7 1–60, 20%
for HPV 16 L1DC* E7 1–52, and 10–15% for HPV 16
L1DC* E7 1–55 for equal amounts of extracted L1 pro-
tein. These results have a high error due to the estimation
of amount of extracted L1 protein. The results, however,
confirm our observations by electron microscopy, that
the particle yield of the above CVLP-constructs is in the
same order of magnitude as that of L1 VLPs.FIG. 2. Western blot analysis of chimeric L1 proteins. Sf9 insect cells
were infected with wild-type and different recombinant baculoviruses
for 3 days. Extracts from infected cells were analyzed by Western Presence of HPV 16 E7 sequences within CVLPs
blotting, using an HPV 16 L1 (Camvir 1, (McLean et al., 1990)) or HPV
16 E7-specific (Triton) antibody. Both antibodies do not react with ex- CVLP DNA constructs based on the HPV 16 L1DC
tracts from cells infected with wild-type baculoviruses. The E7-specific protein were sequenced to verify proper insertion of the
antibody recognizes an epitope within the N-terminus of E7 and there-
E7 fragments. To show that the E7-amino acids are ex-fore does not react with CVLPs HPV 16 L1DC E7 25–75, 50–98, and
pressed from the recombinant baculoviruses, we tested40 –98. The arrows indicate the different forms of L1 and L1/E7 proteins,
L1DC being the fastest and L1DC E7 1–98 the slowest migrating crude extracts of infected Sf9 insect cells by Western
fusion protein. Additional signals are derived from L1, L1/E7 by-prod- blot analysis using either monoclonal anti-HPV 16 L1 or
ucts present in the crude extracts. two different monoclonal anti-HPV16 E7-specific antibod-
ies (Triton anti-E7 antibodies, see Fig. 2; anti-E7 IV,
Oltersdorf et al., data not shown). Using the E7-specificization signal and that insertion of E7 sequences does
not restore transport into the nucleus (see Fig. 5). antibodies, we detected the fusion proteins of the HPV16
L1DC-E7 1–50, 1–98, 1–60 constructs and the HPV16To obtain a more exact estimation of the yield of differ-
ent constructs, we used an antigen capture ELISA to L1DC* E7 1–55, 1–60, 1–65, and 1–70 constructs. The
E7 antibodies did not react with similar quantities of pro-quantify the relative amount of particles. First, we ana-
FIG. 3. Electron micrographs of VLPs and CVLPs derived from BPV (A–C) or HPV 16 (D–I) L1. Virus-like particles were purified through CsCl.
Fractions positive for L1 protein by Western blot were dialyzed and analyzed by electron microscopy. (A) BPV 1 L1 VLPs, (B) BPV 1 L1DC VLPs,
(C) BPV 1 L1DC HPV 16 E7 25 – 75 CVLPs, (D) HPV 16 L1 VLPs, (E) HPV 16 L1DC VLPs, (F) HPV 16 L1DC E7 1–50, (G) HPV 16 L1DC E7 50–98,
(H) HPV 16 L1DC E7 1 – 60, (I) HPV 16 L1DC* E7 1–55. The bar represents 200 nm length.
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FIG. 4. Electron micrographs of HPV 16 CVLPs. (A and B) HPV 16 L1DC* E7 1–52 CVLPs at different magnifications. (C) HPV 16 L1D310 VLPs,
(D and E) HPV 16 L1DC E7 1 – 98 capsomeres. The bar represents 200 nm length.
teins from constructs HPV16 L1DC E7 25–75, 50 – 98 and analysis of chimeric proteins after purification of CVLPs
through CsCl gradients. Using an anti-L1-specific anti-40–98 because of absence of the E7-specific epitopes
for these two monoclonal antibodies (amino acids TDLY body we detected for all clones a major signal with a
mobility corresponding to the expected size of the re-at position 20–23 for antibody E7 IV and amino acids
DTPTLH at positions 4 –9 for the Triton antibody; M.M. spective fusion proteins. This indicates, that there is no
loss of the c-terminal inserted sequences from the CVLPsunpublished). To demonstrate the presence of E7-se-
quences on purified particles we performed Western blot during particle assembly.
FIG. 5. Subcellular localization of L1 and L1/E7 proteins expressed in Trichoplusia Ni High Five insect cells. Cells were infected with wild-type
and different recombinant baculoviruses for 3 days. The L1 or L1/E7 proteins were visualized by immunofluorescence using an anti-L1 specific
antibody (Camvir1) together with an anti-mouse-FITC conjugate.
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FIG. 7. Capsomere and/or capsid specificity of monoclonal antibodies used to quantitiate CVLP and VLP yields. CVLPs (HPV 16 L1DC E7 1–55)
or HPV 16 L1 VLPs were treated with EDTA/DTT and then measured in an antigen-capture ELISA using the three monoclonal antibodies 25/C,
MM07, and Ritti1. Each test was performed in triplicates and the OD values were compared to untreated CVLPs or VLPs, respectively. While ELISA
plates coated with antibodies 25/C and Ritti1 showed increased reactivity to disassembled preparations, the reactivity of antibody MM07 with
treated particles was decreased. We concluded from these experiments that antibody MM07 is reactive in a capsid rather than a capsomere-
specific fashion.
To further investigate, whether the L1/E7 chimeric pro- with an anti-L1 specific monoclonal antibody (MM07) un-
der the same conditions. From this we concluded that thetein detected in CsCl fraction was indeed derived from
complete VLPs and not from capsomeres with a similar E7 epitopes are not accessible in undenatured particles.
However, the assay does not distinguish whether thebuoyant density, we analyzed chimeric CVLPs (HPV 16
L1DC E7 1–55) by velocity centrifugation. For this, we epitope is buried within the capsids or whether it is
folded in a way that does not allow recognition by thesedimented either intact CVLPs or disassembled CVLPs
(see Material and Methods) on 10–15% sucrose gradi- E7 antibody.
ents (see Fig. 8). Using an antigen-capture ELISA with
antibodies specific for either capsids only, or specific Induction of antibodies in mice immunized with
for capsids and capsomeres, we could identify those CVLPs
gradient fractions that contained either only complete
VLPs or only capsomeres. Analyzing sedimentations of To investigate whether the inserted non-L1 peptides
have an influence on the presentation of capsid surfaceuntreated CVLPs with antibodies reacting with capsid as
well as with capsomeres, we detected only complete epitopes involved in virus neutralization, we immunized
mice with HPV 16 L1DC-based CVLPs using Freunds Adju-VLPs (peaked in fractions 3 and 7 in Figs. 8B and 8C).
This indicates that CsCl-gradient-purified CVLPs con- vants. Mice antisera were collected after two booster immu-
nizations and tested for their ability to inhibit hemagglutina-tained only negligible amounts of capsomeres. Fractions
corresponding to complete particles showed to be posi- tion of mouse erythrocytes by complete HPV 16 L1 VLPs
(see Table 2 and Fig. 9). Three mice immunized with HPV16tive for HPV 16 E7, since they produced signals in West-
ern blot analysis using an E7-specific antibody (Triton, L1DC VLPs showed hemagglutination inhibition at dilutions
between 1:4800 and 1:9600 compared to 1:1200 and 1:2400see Fig. 8, bottom). Treatment of CVLPs with chelating
and reducing agents led to a release of capsomeres, as in three mice immunized with wild-type HPV 16 L1 VLPs.
Comparable titers were obtained in three mice immunizeddetected in fractions 18 and 20 (Figs. 8B and 8C). The
same fractions, however, did not react with capsid-spe- with CVLPs from HPV16 L1DC E7 1–50 (1200–4800) and
HPV16 L1DC E7 1–60 (2400–9600). Similarly, using VLPscific antibody MM07 as shown in Fig. 8A. Taken together,
the data indicates that the VLPs generated from chimeric purified from insect cells infected with recombinant bacu-
lovirus expressing HPV16 L1DC plus HPV 16 L2, threeL1/E7 protein contain the E7 peptides.
Using electron microscopy, we examined CVLPs mice developed hemagglutination inhibition titers between
1200 and 4800. As negative control, we used the samestained with gold-labeled antibodies to locate the E7 se-
quences within the particles. However, we did not ob- antisera in hemagglutination assays with BPV 1 L1 VLPs
as antigen. None of the 15 sera against HPV 16 L1 (VLPs orserve labeling of CVLPs using two different anti-HPV 16
E7 monoclonal antibodies (Triton and E7 IV) and gold- CVLPs) showed significant inhibition of hemagglutination.
Borderline reactivity was observed with one serum raisedlabeled anti-mouse antibodies although CVLPs reacted
FIG. 6. Uptake and transport of CLVPs by CV-1 cells in vitro. (A –E) CV-1 cells were incubated with HPV 16 L1DC* E7 1–55 VLPs for 1 hr at 47.
Temperature was then shifted to 377 to allow uptake and transport of CVLPs. CVLPs were then detected by immunofluorescence. (A) CVLP stained with
an anti HPV 16 E7 antibody (Triton). (B–E) CVLPs stained with an anti-HPV 16 L1 antibody (Camvir1, (McLean et al., 1990)). (C) Immunofluorescence for
E7 and L1, nuclei are stained with DAPI. (D and E) Localization of CVLPs in a perinuclear pattern.
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FIG. 8. Sucrose sedimentation of CVLPs. CsCl-purified CVLPs (HPV 16 L1DC E7 1–55) were treated overnight with EDTA/EGTA/DTT to allow
disassembly of particles into capsomeres. As a control, we diluted CVLPs in a buffer without chelating or reducing agents. Samples were layered
onto a 10– 50% sucrose gradient and centrifuged at 250,000 g for 2 or 4 hr. Gradients were then collected and fractions tested in an antigen-capture
ELISA using the capsid-specific antibody MM07 (A) or the capsid/capsomere-specific antibodies Ritti1 (B) and 25/c (C). After 2 hr centrifugation we
found a peak of complete VLPs in fraction 7, after 4 hr in fraction 3. These fractions were also positive in Western blot analysis using an anti-E7-
specific antibody (D). Capsomeres were found in fraction 20 after 2 hr and fraction 18 after 4 hr centrifugation (B and C).
against HPV 16 L1DC serum at the highest concentration low sensitivity of the test using BPV VLPs to agglutinate
mouse erythrocytes (see Fig. 9).tested (1:300). Sera of mice immunized with BPV 1 L1 and
BPV 1 L1DC VLPs (the latter one from L1/L2 double infec- By E7-specific peptide ELISA, we tested sera from mice
immunized with truncated HPV 16 L1 (HPV 16 L1 DC) andtions) neutralized hemagglutination caused by BPV VLPs
but not by HPV 16 VLPs. We did not achieve hemagglutina- two different chimeric VLP constructs (HPV 16 L1DC E7
1–50 and HPV 16 L1DC E7 1–60). The E7-specific peptidetion-inhibition using two sera from mice immunized with
BPV 1 L1DC-HPV 16E7 25–75 CVLPs, possibly due to a used as antigen in this assay is encoded by the two chime-
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TABLE 2
Hemagglutination (HA)-Inhibition by Antisera Raised against CVLPs
Animal No. Serum against Titer of HPV 16 VLP HA-inhibition Titer of BPV 1 VLP HA-inhibition
1– 3 HPV16 L1 2400, 2400, 1200 neg., neg., neg.a
4– 6 HPV16 L1DC/L2 4800, 1200, 4800 neg., neg., neg.a
7– 9 HPV16 L1DC 9600, 9600, 4800 neg., 300,b neg.a
10– 12 HPV16 L1DC E7 1-50 1200, 4800, 2400 neg., neg., neg.a
13– 15 HPV16 L1DC E7 1-60 2400, 9600, 4800 neg., neg., neg.a
16– 18 BPV1 L1DC neg., neg., neg.a 300, 300, 600
19, 20 BPV1 L1/L2 neg., neg.a 300, 1200
21, 22 BPV1 L1DC/L2 neg. neg.a 600, 600
23, 24 BPV1 L1DC E7 25–75 neg., neg.a neg., neg.a
Note. We used either HPV 16 L1 VLPs or BPV 1 VLPs to hemagglutinate mouse erythrocytes. VLPs were preincubated with various dilutions of
24 different antisera before they were added to mouse red blood cells. The highest titer that gave complete inhibition of hemagglutination is given.
a Lowest serum dilution tested was 1:300.
b A slight inhibition of hemagglutination was observed at the lowest serum dilution.
ric VLPs. A specific reaction was measured only for one of different monoclonal antibodies, which recognize conforma-
tional epitopes on HPV 16 L1 VLPs, were tested for theirsix sera of mice immunized with CVLPs, indicating that the
E7 portion of CVLPs is a rather weak inducer of a humoral ability to react with HPV 16 L1DC* E7 1–55 CVLPs. Both
antibodies (H16.V (Christensen et al., 1996a) and 25/C; M.M.,immune response (data not shown).
By ELISA, we screened a total 480 hybridoma clones unpublished) recognized the chimeric particles using an
antigen-capture ELISA, immunofluorescence and immuno-derived from a mouse immunized with the CVLP HPV 16
L1 DC E7 1–60 for the production of antibodies against gold electron microscopy (data not shown).
chimeric as well as against wild-type HPV 16 VLPs. Of the
154 clones reactive against HPV 16 L1 DC E7 1–60 (OD Chimeric virus-like particles bind to cells and are⁄ 0.5), we found 142 that reacted significantly (OD ⁄ 0.4) internalized
with wild-type HPV 16 L1 VLPs (data not shown). These
findings indicate that VLPs and CVLPs exhibit a high struc- We wanted to investigate, whether the CVLPs are still
able to interact with the cellular receptor for papillomavi-tural resemblance. Similar data were obtained when two
FIG. 9. Hemagglutination inhibition by the use of antisera raised against CVLPs. HPV 16 or BPV 1 VLPs were preabsorbed with antisera from
mice immunized with different VLP or CVLPs and then used to hemagglutinate mouse red blood cells. The figure shows the different dilutions of
antisera and which proteins were used for immunization. Note: 16L1DC used in this experiment was coexpressed with HPV16L2 and the three
antisera were derived from animals No. 4–6 in table 2.
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ruses. We tested particles of the constructs HPV 16 thermore, as it was reported in earlier studies (Tan et
al., 1995; Kennedy et al., 1991, 1990), truncation of theL1DC and HPV 16 L1DC with inserts HPV 16 E7 1 –
50, 1–60 and HPV 16 L1DC* 1–55 in hemagglutination carboxy-terminus of HPV 16 L1 leads to a partial loss
of negative control elements on L1-specific mRNA, thusassays. All of these particles were able to hemagglutti-
nate mouse erythrocytes, albeit at 2–8 times lower titers increasing the overall expression of the L1 protein.
We showed that the modification introduced to gener-than HPV 16L1 VLPs (data not shown). These data indi-
cate that CVLPs are able to interact with the papillomavi- ate CVLPs does not interfere with basic structural and
functional properties of the particles. HPV 16 CVLPs arerus receptor present on mouse red blood cells. We did
not pursue to investigate whether the lower titers were able to bind and penetrate cells in vitro and are inducing
a neutralizing antibody response as monitored by inhibi-due to lower affinity in binding or due to lower particle
numbers in the various preparations. tion of hemagglutination of mouse red blood cells by HPV
16 VLPs. Although sera against CVLPs scored positive inTo further study the interaction of CVLPs and host
cells, we incubated CV-1 monkey kidney epithelial cells hemagglutination inhibition, we cannot exclude that
some of the neutralizing epitopes are lost on these parti-with particles generated by the construct HPV 16 L1DC*
E7 1–55. Experiments were performed as we described cles. Hemagglutination inhibition was used to demon-
strate the neutralizing activities of those anti- HPV L1earlier for BPV 1 virions (Zhou et al., 1995). Particles
were added to cells and the fate of the L1 antigen was antibodies, which interfere directly with binding of PV
virions or VLPs to cells (Roden et al., 1995, 1996b). How-examined by immunofluorescence using a L1-specific
antibody (Camvir 1). We observed that the L1 antigen ever, anti-BPV 1 L2 antibodies were reported to neutralize
transforming activities of BPV virions in vitro. Apparently,bound to the cellular membrane and later accumulated
in the cytoplasm, in particular in a perinuclear pattern these and likely some of the L1-specific neutralizing anti-
bodies do not interfere with the interaction of virions and(see Figs. 6D and 6E). After overnight incubation, the L1
protein was located in large cytoplasmic lumps (Figs. the cellular receptor for papillomaviruses (Roden et al.,
1994b). Using hemagglutination inhibition does not allow6A–6C), as described for BPV 1 virions (Zhou et al., 1995),
suggesting an accumulation in the endoplasmic retic- the detection of antibodies, which neutralize the virus
downstream of the binding event. Therefore, we do notulum.
We obtained similar results using an HPV 16 E7-spe- know whether CVLPs also induce antibodies of such
specifities.cific antibody. This antibody proved to be useful in localiz-
ing the chimeric protein within the cells. By double immu- We failed to detect significant production of antibodies
against the E7 after immunizing mice with CVLPs. Fur-nofluorescence, we noticed a colocalization of the L1-
and E7-specific signals (Figs. 6A–6C). However, in some ther, CVLPs did not react with E7-specific antibodies
when examined by electron microscopy using gold-la-of the cytoplasmic locations, we can detect the chimeric
protein only by the L1-specific antibody (compare Fig. 6A beled antibodies against E7. Similarly, E7-specific anti-
bodies reacted only with a fraction of CVLPs after bindingto 6B). The reason for this different reactivity might be an
intracellular processing of the CVLPs, which eventually and uptake of particles by cells in vitro. These observa-
tions are consistent with a partial or complete internalmakes the E7 epitope accessible for the antibody.
localization of the inserted sequences within the CVLPs.
However, another explanation is that the E7 itself isDISCUSSION
folded in a way that does not allow binding of the E7-
specific antibodies. Antibodies raised against L1/E7We have developed chimeric HPV 16 papillomavirus-
like particles (CVLPs) that are potentially useful as a CVLPs might therefore not react with the E7 epitopes
presented in the ELISA that we used for screening.therapeutic and prophylactic vaccine. The most efficient
formation of capsids was obtained with a recombinant Our goal was to generate CVLPs containing major por-
tions of the HPV 16 E7 protein. We hypothesize that thesein which the carboxy-terminal 34 amino acids of HPV 16
L1 were replaced by amino acids 1–50 of HPV 16 E7. In particles will be able to induce a CTL response against
L1 and the E7 portion. In fact, we and others have gener-this case, the efficiency of VLP production was similar
when compared to the unmodified HPV 16 L1 protein. ated preliminary data, indicating that in mice CTLs can
be induced after immunization with VLPs or CVLPs (I.The L1 carboxy-terminus encodes the nuclear localiza-
tion signal for many different papillomaviruses but shows Jochmus et al., unpublished; Schiller and Roden, 1995;
W. M. Kast, personal communication). In addition, induc-otherwise relatively low sequence homology between
different PV types (Zhou et al., 1991a). The deletion of tion of a CTL response using empty viral capsids was
demonstrated for Hepatitis B virus-VLPs (Schirmbeck etthe carboxy-terminal amino acids of the L1 protein has
potential advantages in terms of efficiency and fidelity of al., 1996). In humans, three peptides derived from the E7
protein have been shown to stimulate specific HLA-VLP production. First, the VLPs are easier to be extracted
and purified, if not associated with the nuclear matrix A0201 restricted CTLs either in vitro using peripheral
blood monocytes or in vivo by vaccination of transgenicand deletion of the NLS can also reduce the intrinsic
ability of the L1 protein to incorporate cellular DNA. Fur- mice expressing a HLA-A2kb hybrid molecule (Ressing
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et al., 1995). However, the relevance of these peptides boxy-terminally truncated HPV 11 L1 protein, however,
we did not investigate whether the deleted parts of HPVas E7-specific T-cell epitopes as well as epitopes re-
stricted by other HLA-alleles is not yet known for the 11 L1 can be replaced by non-L1 amino acids. The data,
however, suggests that the C-terminus of the L1 proteinhuman system. Lacking this knowledge, we intended to
insert the complete HPV 16 E7 protein into the CVLPs. of other HPV types is not required for capsid formation
and that CVLPs other than HPV 16 can be produced inWe observed that extending the E7 insert beyond the
first 55 amino acids either leads to inefficient particle a similar manner.
It can be assumed that immunization of animals asproduction or has a considerable impact on the particle
structure. We believe that this observation can only in well as human subjects with CVLPs leads to the produc-
tion of neutralizing antibodies, that are able to inhibitpart be explained by the length of the insert. In case of
constructs bearing inserts of identical or shorter length, binding of CVLPs to cells. Neutralizing antibodies might
as well be present in patients suffering from HPV-associ-derived from the carboxy-terminus of E7 (e.g., HPV 16
L1DC E7 50–98), we observed a much lower particle ated diseases (Christensen et al., 1992). These antibod-
ies might limit the immune-response to booster immuni-yield. We assume that sequences between amino acid
positions 55 and 70 of HPV 16 E7 are interfering with zations and thus limit the response to the inserted non-
L1 protein. This potential problem might be overcome bythe proper particle assembly. Possibly the four cysteines
located in this region are forming disulfide bonds with the use of CVLPs with the same non-L1 sequences, but
with a L1 protein derived from a different HPV type, sinceeach other or with cysteine residues within the L1 pro-
tein. Similarly, a HPV 16 L1DC construct where 30 amino no significant cross-type-neutralizing antibody response
exists (Roden et al., 1996b).acids of the influenza matrix protein were inserted, pro-
duced only small amounts of VLPs. Another CVLP con- We investigated CVLPs from HPV 16 L1 and E7 pro-
teins as a model system for delivery of peptides intostruct, containing a relatively short insert of 10 amino
acids of the carboxy-terminus of the SV40 T antigen, was cells. We are confident that it is feasible to insert other
HPV-specific (e.g., the E6 protein) as well as non-HPVcompletely deficient for assembly, suggesting that the
sequence of the inserted protein (60% of the inserted sequences into these particles, especially known cyto-
toxic T-cell epitopes from tumor antigens. The broad hostamino acids are prolines) can interfere with particle for-
mation. range of PV particles allows binding and uptake of CVLPs
by a large variety of cell types from different species,The construct in which the complete HPV 16 E7 was
inserted into the HPV 16 L1DC clone produced particles opening the use of CVLPs for a wide range of applica-
tions.at very poor yields. However, expression of this chimeric
protein led to the formation of large quantities of capso-
meres, which assembled into aggregations as visualized ACKNOWLEDGMENT
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